XML 22 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
Equity Instruments - Vyrix Stock Option Activity (Detail) (Vyrix Pharmaceuticals [Member], USD $)
6 Months Ended 9 Months Ended
Jun. 30, 2014
Mar. 31, 2015
Vyrix Pharmaceuticals [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of Options, Beginning Balance   950,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Number of Options, Granted   0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Number of Options, Exercised   0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Number of Options, Forfeited/Cancelled   0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Number of Options, Ending Balance 950,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
950,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Number of Options, Exercisable   475,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Number of Options, Available for grant   4,050,000rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Weighted Average Exercise Price, Beginning Balance   $ 0.70us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Weighted Average Exercise Price, Granted   $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Weighted Average Exercise Price, Exercised   $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Weighted Average Exercise Price, Forfeited/Cancelled   $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Weighted Average Exercise Price, Ending Balance $ 0.70us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
$ 0.70us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Weighted average exercise price, Exercisable   $ 0.70us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Weighted Average Remaining Contractual Life, Outstanding 9 years 6 months 15 days 8 years 9 months 15 days
Weighted Average Remaining Contractual Life, Exercisable   8 years 9 months 15 days
Aggregate Fair Value, Beginning Balance   $ 417,000rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateFairValue
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Aggregate Fair Value, Ending Balance 417,000rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateFairValue
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
417,000rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateFairValue
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember
Aggregate Fair Value, Exercisable   $ 208,000rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateFairValue
/ dei_LegalEntityAxis
= rswn_VyrixPharmaceuticalsIncMember